Report overview
The occurrence of kidney cancer has increased in the recent years. Excessive smoking, rise in obesity because of sedentary life routines and increased consumption of alcohol are some of the causes of kidney cancer. The most common type of cancer is Renal Cell Carcinoma (RCC).Immunotherapies or targeted therapies are the most common prescribed treatments for kidney cancer.
This report contains market size and forecasts of Kidney Cancer Therapeutics and Diagnostics in Global, including the following market information:
Global Kidney Cancer Therapeutics and Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Kidney Cancer Therapeutics and Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cystoscopy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer Therapeutics and Diagnostics include Bayer, Hoffmann La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Amgen, Genentech and Cerulean Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Therapeutics and Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, by Type, 2021 (%)
Cystoscopy
Biopsy
Intravenous Pyelogram
CT Scan
Kidney Ultrasound
Others
Global Kidney Cancer Therapeutics and Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Pharmaceutical Labs
Genomics Laboratories
Others
Global Kidney Cancer Therapeutics and Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Therapeutics and Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Kidney Cancer Therapeutics and Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Hoffmann La Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Amgen
Genentech
Cerulean Pharma
Seattle Genetics
